Axsome Therapeutics Inc. (AXSM)

Axsome Therapeutics, Inc. AXSM reported better-than-expected second-quarter financial results on Monday.

Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Ari Maizel - Chief Commercial Officer Darren Opland - Corporate Participant Her...

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to ...

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1.24 per share a year ago.

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axsome's valuation is driven by its promising pipeline, with Auvelity as a proven commercial success and Symbravo and AXS-12 showing solid potential. Recent setbacks include the FDA's refusal to file ...

Should you invest in stocks right now? Some might be hesitant to do so because of the volatility broader equities have faced this year.

Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after ma...

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?